Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Immunology
Facteur d'impact: 1.352 Facteur d'impact sur 5 ans: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimer: 1040-8401
ISSN En ligne: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v27.i5.20
pages 415-436

Targeting OX40 and OX40L for the Treatment of Autoimmunity and Cancer

William L. Redmond
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St., No. 5F37, Portland, OR 97213, USA
Andrew D. Weinberg
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St., No. 5F37, Portland, OR 97213, USA

RÉSUMÉ

The optimal activation of naïve T cells requires TCR−mediated recognition of cognate peptide−MHC complexes on antigen presenting cells in the presence of costimulatory signals. Although signals provided via CD28−B7 interactions are important for enhancing the initial T−cell response, other costimulatory signals are required for sustaining the response and promoting both T−cell differentiation and survival. In particular, engagement of OX40 (CD134) by its natural ligand OX40L (CD134L) or OX40 agonists has been shown to provide key signals that can augment CD4 and CD8 T−cell responses. Importantly, numerous studies have highlighted the ability of OX40−specific agonists or antagonists to enhance antitumor immunity or ameliorate autoimmune disease, respectively. On the basis of these studies, the development of OX40− and OX40L−specific reagents has been pursued for clinical use. Given the emerging role of OX40 and OX40L as novel therapeutic targets, this review will focus on the cellular and molecular mechanisms of OX40−mediated T−cell costimulation with a special emphasis on the role of OX40-OX40L interactions in the etiology and treatment of autoimmunity and cancer.


Articles with similar content:

The Role of OX40-Mediated Co-stimulation in T-Cell Activation and Survival
Critical Reviews™ in Immunology, Vol.29, 2009, issue 3
Carl E. Ruby, Andrew D. Weinberg, William L. Redmond
The Role of Forkhead Box 1 (FOXO1) in the Immune System: Dendritic Cells, T Cells, B Cells, and Hematopoietic Stem Cells
Critical Reviews™ in Immunology, Vol.37, 2017, issue 1
Adriana Alicia Cabrera-Ortega, Daniel Feinberg, Carlos Rossa, Jr., Youde Liang, Dana T. Graves
Activation of Natural Killer Cells by Probiotics
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Nabil Aziz , Benjamin Bonavida
The Phenotype and Function of Lung Dendritic Cells
Critical Reviews™ in Immunology, Vol.25, 2005, issue 6
Allison T. Thiele, Kena A. Swanson, Tina L. Sumpter, Tonya J. Webb, David S. Wilkes
IL-21 Is an Immune Activator That also Mediates Suppression via IL-10
Critical Reviews™ in Immunology, Vol.30, 2010, issue 6
Warren J. Leonard, Rosanne Spolski